AMI, Spectocor and Medi-Lynx: Three Monitoring Choices, One Medicare Option

AMI, Spectocor and Medi-Lynx reached a $13.4 million PocketECG settlement over allegations that they steered Medicare patients into higher-priced cardiac telemetry. The government alleged that the companies designed the enrollment process to select telemetry even when doctors wanted a less expensive service. Someone inside enrollment, sales or billing could see the contradiction: a device sold as offering several monitoring choices, with a system that allegedly took the cheaper choices away.

The Department of Justice announced the settlement on June 26, 2017. MEDICALgorithmics manufactured PocketECG. AMI and Spectocor operated independent diagnostic testing facilities and marketed the device under an exclusive distribution agreement. Their business included the monitoring service behind the hardware. The whistleblower’s complaint describes technicians receiving the device’s data and providing physicians with results and analysis.

How PocketECG Enrollment Allegedly Steered Medicare Patients to Telemetry

AMI and Spectocor marketed PocketECG for Holter, event and telemetry monitoring, with telemetry carrying the highest reimbursement. The government alleged that AMI and Spectocor used the online enrollment process to steer doctors toward that service for Medicare patients from 2011 through 2016.

The whistleblower’s complaint describes a portal that collected patient and insurance information, diagnoses, symptoms, physician information and the monitor selection. A drop-down menu offered the monitor choices. The allegation was that the insurance entry controlled which PocketECG choice appeared:

For patients whose private insurance did not cover telemetry, the complaint said the portal offered PocketECG Event. Private insurance that covered telemetry produced the telemetry option instead. The alleged dividing line was what the insurer would pay. A doctor could arrive intending to order event monitoring and leave with a telemetry enrollment.

The complaint also alleged that the companies processed telemetry enrollments without medical records supporting the need for that service. Some enrollments carried diagnosis codes unrelated to the covered indication. The system allegedly made the expensive selection easy even when the patient’s chart did not support it.

Private-Patient Waivers Allegedly Used to Win Medicare Business

Spectocor allegedly used benefits for privately insured patients to win access to practices with Medicare and TRICARE patients. The complaint described a sales offer that joined the two sides of the business:

The complaint alleged that sales representatives had authority to offer those waivers to establish relationships with practices serving substantial government-insured populations. The private-patient concession helped get the account. The Medicare telemetry billing was the alleged payoff.

How the Enrollment Choice Reached the Claim

The alleged enrollment scheme reached both the monitoring company’s bill and the physician’s bill. In its account of cardiac-monitoring reimbursement, the complaint identifies CPT code 93229 for technical telemetry services and CPT code 93228 for the professional component. It alleged that Spectocor billed the technical component and caused providers to bill the professional component as telemetry when event monitoring was the appropriate service.

The service selected during enrollment could travel into the claim as a particular billing code. The clinical records answered a separate question: why that patient needed the selected level of monitoring. Connecting those records shows how a choice made in a supplier’s portal could become a request for Medicare money.

The report delivered to the doctor added another revealing comparison. The whistleblower alleged that PocketECG supplied the same analysis and patient information whether used for event monitoring or telemetry. According to the complaint, the telemetry report added documentation of daily measurements, but no additional analysis, documentation of abnormalities or other substantive data. The whistleblower said examples of both reports had been provided to the government.

The device was marketed as flexible. The reimbursement treatment allegedly followed the payer, while the analysis delivered to the doctor remained the same.

What Evidence Is Needed to Prove Fraud?

In an enrollment scheme like this one, our whistleblower experts work with you to connect what the doctor intended, what the portal allowed and what Medicare was charged. The clinical records, sales instructions and monitoring reports help us explain how those choices became claims.

The 2020 Journal of Forensic and Investigative Accounting article A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud explains that the payment claim is central to the False Claims Act inquiry. It identifies requests that misstate the services rendered as one form of false claim. Applied to PocketECG, that means following the payer-dependent enrollment choice through to the service charged to Medicare.

An enrollment employee may understand which selections disappeared after the insurance information was entered. A sales employee may know the promises made to a practice. A billing employee may see how the resulting service was coded. Those views can connect the design of the process with what it cost the government. Our whistleblower experts use that knowledge to build your strongest cardiac-monitoring fraud case.

The Same Enrollment Procedure at Medi-Lynx

The government alleged that Medi-Lynx used the same enrollment procedure and marketing scheme from 2013 through 2016, resulting in false Medicare claims. A former co-owner of AMI and Spectocor formed Medi-Lynx as another independent diagnostic testing facility in 2013, and it marketed PocketECG under an agreement with MEDICALgorithmics.

The manufacturer acquired a controlling interest in Medi-Lynx in September 2016. The alleged enrollment mechanism thus reached another monitoring business using the same device. The relationship among manufacturer, testing facility and ordering physician mattered throughout the case.

CardioNet and LifeWatch Show the Wider Pattern

Cardiac-monitoring cases have repeatedly concerned the choice of a more expensive service. CardioNet’s 2015 settlement addressed allegations of billing for unnecessary higher-level mobile cardiac outpatient telemetry.

LifeWatch’s 2023 settlement concerned allegations that enrollment design and instructions caused higher-priced telemetry when physicians intended lower-level monitoring. That is the particularly close parallel to PocketECG: the process used to order the service allegedly changed which service reached the bill.

The PocketECG Settlement Payments

AMI and Spectocor took the largest share of the settlement, agreeing to pay $9.56 million. Their president and owner agreed to pay $1 million, while Medi-Lynx and its majority owner, MEDICALgorithmics, agreed to pay $2.89 million.

How Much Is a Whistleblower Claim Worth?

The Justice Department announced a $2.4 million whistleblower award for the former AMI employee who brought this qui tam case.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Saw What the Enrollment System Did

If you know how a monitoring company’s enrollment choices, sales promises or billing instructions changed what Medicare was charged, talk with our whistleblower experts. We build the case with you and bring in healthcare fraud whistleblower lawyers who understand cardiac-monitoring claims. From your first account of the system through the pursuit of a recovery, we stay on your side.